Posted by Michael Wonder on 15 Oct 2021
NICE clears Opdivo for resected oesophageal or gastro-oesophageal junction cancer
15 October 2021 - The UK NICE has recommended BMS' Opdivo (nivolumab) as a treatment option for certain resected oesophageal or gastro-oesophageal junction patients.
Opdivo has been cleared as an adjuvant treatment of completely resected oesophageal or gastro-oesophageal junction cancer in adults who have residual disease following neo-adjuvant chemoradiotherapy.
